ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
COVID-19 infection in lipodystrophy syndromes
Gökçen Güngör Semiz 1 , Tevfik Demir 1 , Ilgin Yildirim Simsir 2 , İsmail Selimoğlu 3 , Müge Yılmaz 4 , Mehmet Çağrı Ünal 1 , Hülya Ellidıkuz 5 , Hüseyin Onay 6 , Ramazan Gen 7 & Bahri Evren 8
1Dokuz Eylul University, Faculty of Medicine, Internal Medicine, Division of Endocrinology and Metabolism, İzmir, Turkey; 2Ege University, Faculty of Medicine, Internal Medicine, Division of Endocrinology and Metabolism, İzmir, Turkey; 3Dokuz Eylul University, Faculty of Medicine, Internal Medicine, İzmir, Turkey; 4Ege University, Faculty of Medicine, Internal Medicine, İzmir, Turkey; 5Dokuz Eylul University Institute of Oncology, Department of Preventive Oncology, İzmir, Turkey; 6Ege University, Faculty of Medicine, Medical Genetics, İzmir, Turkey; 7Mersin University Faculty of Medicine, Internal Medicine, Division of Endocrinology and Metabolism, Mersin, Turkey; 8İnönü University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Malatya, Turkey
Purpose: The coronavirus disease 2019 (COVID-19) has a high morbidity and mortality in patients with chronic disorders. This study was aimed at assessing the frequency and outcomes of COVID-19 in patients with lipodystrophy syndrome and investigating the effect of restricted access to the hospital during pandemic on metabolic parameters.
Methods: A survey comprising descriptive questions about the situation of the patients during the COVID-19 pandemic was created and performed by a phone call. Patients were asked if they had COVID-19 so far; if so, the hospitalisation, the need for intensive care and the oxygen requirement, COVID-19 treatment and ongoing findings after COVID-19 infection were questioned. Laboratory data from hospital records were retrospectively analysed, and the results after the COVID-19 period, if any, were obtained from the patients.
Results: A total of 71 patients were included. Patients with lipodystrophy had at least one comorbid disease; diabetes mellitus was the most common (87.1%). Six patients (8.5%) stated that they had COVID-19 infection, of which three were hospitalised and one was followed up in the intensive care unit. No death was reported. Microalbuminuria was significantly worsened in all patients compared to their pre-pandemic status.
| Yes, n (%) | No, n (%) | |
| Hospitalisation | 3(50) | 3 (50) |
| Intensive care unit | 1 (16.7) | 5 (83.3) |
| Oxygen support | 2 (33.3) | 4 (66.7) |
| Abbreviations: COVID-19, coronavirus disease 2019. | ||
Conclusions: Patients with lipodystrophy have a high risk of severe COVID-19 due to their multiple comorbidities. Further studies with larger patient groups are needed to verify these findings. Metabolic parameters of patients with rare diseases were deteriorated during the pandemic.
| Pre-pandemic period (Mean ± SD) | Pandemic period (Mean ± SD) | P | |
| HbA1c (%) | 7.08 ± 1.69 | 7.29 ± 1.82 | 0.741 |
| Spot Urine microalbumin (mg/dl) | 311.61 ± 1050.32 | 371.52 ± 749.84 | 0.013 |
| TC (mg/dl) | 186.09 ± 72.68 | 178.91 ± 84.35 | 0.545 |
| LDL cholesterol (mg/dl) | 98.36 ± 71.50 | 92.00 ± 52.67 | 0.451 |
| HDL cholesterol (mg/dl) | 40.05 ± 23.04 | 36.53 ± 15.48 | 0.593 |
| TG (mg/dl) | 340.81 ± 392.77 | 379.83 ± 687.51 | 0.379 |
| Abbreviations: SD, standard deviation; HbA1c, glycated haemoglobin; TC, total cholesterol; LDL, low-density lipoprotein; TG, triglycerides; HDL, high-density lipoprotein. | |||
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more